Tamoxifen Therapy for Myotubular Myopathy

Overview

This is a phase 1 / 2, randomized, double-blinded, single cross-over study, with a washout period between treatment regimens, to test the efficacy and safety of tamoxifen therapy to improve motor and respiratory function in males with XLMTM.

Full Title of Study: “TAM4MTM: A Phase 1/2 Randomized, Placebo-Controlled, Double-Blinded, Single Crossover Study to Determine the Safety and Efficacy of Tamoxifen Therapy for Myotubular Myopathy (XLMTM)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: August 31, 2024

Detailed Description

Pre-clinical studies in Mtm1 knockout mice (a model of XLMTM) demonstrated prolonged survival, increased motor function (including muscle strength), and improved muscle histopathology with tamoxifen treatment. Based on these data, and the known safety profile of the drug in humans, we hypothesize that tamoxifen treatment will be safe and will improve motor and respiratory function in XLMTM patients. This is a randomized, double-blinded, single crossover clinical trial to test this hypothesis and determine the safety and efficacy of tamoxifen in improving motor and respiratory function in MTM patients. Each subject will serve as his own control during the placebo phase of the study. As treatments for XLMTM are current not available, this study addresses a critical unmet need by testing a therapy that, if effective, may serve as a primary treatment, or in the future as an adjunct to other therapies in development.

Interventions

  • Drug: ApoTamox 10mg
    • All participants will receive tamoxifen (ApoTamox) for approximately 6 months (6 months + 1 week). Participants and study staff will be blinded as to whether the participants are starting with the placebo or the drug. Depending on randomization, drug or placebo will be dispensed at the end of the t=0 study visit (Phase 1). Dosing will commence the day after the t=0 study visit. At the end of Phase 1, participants will enter a ‘washout’ period, when they will cease treatment. After approximately 3 months of washout, participants will cross-over to the other treatment regimen and receive the other interventional product (IP) for the final 6 months of their study participation (Phase 2).
  • Drug: Placebo
    • placebo comparator

Arms, Groups and Cohorts

  • Experimental: Drug: ApoTamox 10mg
    • Drug: Tamoxifen (tamoxifen citrate); ApoTamox 10 mg tablets orally twice daily for 6 months
  • Placebo Comparator: Placebo
    • Placebo (no active ingredients) tablets orally twice daily for 6 months

Clinical Trial Outcome Measures

Primary Measures

  • Motor Function Measure 32 (MFM32)
    • Time Frame: Baseline to 15 Months
    • Mean change from baseline of Motor Function Measure 32 for subjects aged 4 and older
  • Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders for subjects aged 2-4 years (CHOP INTEND)
    • Time Frame: Baseline to 15 months
    • Mean change from baseline of Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders for subjects aged 2-4 years
  • 10 meter walk test
    • Time Frame: Baseline to 15 months
    • Mean change from baseline in velocity in 10 meter walk test for ambulant participants

Secondary Measures

  • Change in pulmonary function testing scores 1) Forced Expiratory Volume in the first second
    • Time Frame: Baseline to 15 months
    • Mean change from baseline in participants without invasive respiratory support
  • Change in pulmonary function testing scores 2) Forced Vital Capacity
    • Time Frame: Baseline to 15 months
    • Mean change from baseline in participants without invasive respiratory support
  • Change in pulmonary function testing scores 3) Peak Cough Flow
    • Time Frame: Baseline to 15 months
    • Mean change from baseline in participants without invasive respiratory support
  • Change in pulmonary function testing scores 4) Maximum Expiratory Pressure
    • Time Frame: Baseline to 15 months
    • Mean change from baseline in participants without invasive respiratory support
  • Change in pulmonary function testing scores 5) Maximum Inspiratory Pressure or Sniff Inspiratory Pressure
    • Time Frame: Baseline to 15 months
    • Mean change from baseline in participants without invasive respiratory support
  • invasive ventilation – time off ventilation
    • Time Frame: Baseline to 15 months
    • Mean change in time off ventilator for participants dependent on invasive respiratory support
  • Incidence and severity of Adverse Events related to the treatment [ Time Frame: 15 Months ]
    • Time Frame: Baseline to 15 months
    • Incidence of serious adverse events and adverse events throughout the study, as assessed by CTCAE v4.0
  • micro RNA 133a (miR133a)
    • Time Frame: Baseline to 15 months
    • Assess miR133a as a biomarker of XLMTM

Participating in This Clinical Trial

INCLUSION CRITERIA 1. Male 2. Patients ages 6 months and older may participate. 3. XLMTM resulting from a confirmed mutation in the Myotubularin 1 (MTM1) gene 4. Patients over 18 years of age and parent(s)/legal guardian(s) of patients <18 years of age must provide written informed consent prior to participating in the study and informed assent will be obtained from minors, or at least 7 years of age when required by regulation. 5. Willing and able to comply with all protocol requirements and procedures. EXCLUSION CRITERIA 1. Other disease which may significantly interfere with the assessment of myotubular myopathy (MTM) and is clearly not related to the disease, at the discretion of the qualified investigator. 2. Has undergone surgery or hospitalization < 3 months before starting TAM4MTM (at t = -3 months), or has surgery scheduled during the 18 months of participation in TAM4MTM, which will impede motor assessments in the opinion of the Investigator. 3. Has a history of thromboembolic events 4. Currently enrolled in a treatment study for XLMTM or receiving treatment with an experimental therapy other than pyridostigmine. 5. Treatment with pyridostigmine for < 6 weeks duration (must be greater than 6 weeks to be included in TAM4MTM). 6. Use of concomitant medication known to inhibit CYP2D6 and/or CYP3A4, including clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, verapamil, goldenseal and grapefruit, paroxetine, troleandomycin, rifampin, phenobarbital, aminoglutethimide, medroxyprogesterone, amiodarone, haloperidol, indinavir, ritonavir, quinidine, rifampicin, or any selective serotonin reuptake inhibitor (SSRI). 7. Subject has a contraindication to tamoxifen or its ingredients

Gender Eligibility: Male

Minimum Age: 6 Months

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • James Dowling
  • Collaborator
    • Canadian Institutes of Health Research (CIHR)
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: James Dowling, Staff clinician and senior scientist – The Hospital for Sick Children
  • Overall Official(s)
    • Jame J Dowling, MD, PhD, Principal Investigator, The Hospital for Sick Children
  • Overall Contact(s)
    • Keshini Devakandan, MSc, 4168137654, keshini.devakandan@sickkids.ca

References

Amburgey K, Tsuchiya E, de Chastonay S, Glueck M, Alverez R, Nguyen CT, Rutkowski A, Hornyak J, Beggs AH, Dowling JJ. A natural history study of X-linked myotubular myopathy. Neurology. 2017 Sep 26;89(13):1355-1364. doi: 10.1212/WNL.0000000000004415. Epub 2017 Aug 25.

Maani N, Sabha N, Rezai K, Ramani A, Groom L, Eltayeb N, Mavandadnejad F, Pang A, Russo G, Brudno M, Haucke V, Dirksen RT, Dowling JJ. Tamoxifen therapy in a murine model of myotubular myopathy. Nat Commun. 2018 Nov 19;9(1):4849. doi: 10.1038/s41467-018-07057-5.

Gayi E, Neff LA, Massana Munoz X, Ismail HM, Sierra M, Mercier T, Decosterd LA, Laporte J, Cowling BS, Dorchies OM, Scapozza L. Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy. Nat Commun. 2018 Nov 19;9(1):4848. doi: 10.1038/s41467-018-07058-4.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.